Vimian Group (OM:VIMIAN) - Aandelenkoers, Nieuws & Analyse

VIMIAN Overzicht aandelen

Vimian Group AB (publ) houdt zich wereldwijd bezig met diergezondheid. Meer informatie

VIMIAN fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Verhandeld tegen 16.1% onder onze schatting van de reële waarde

De winst zal naar verwachting met 89.81% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Grote eenmalige posten die de financiële resultaten beïnvloeden

Aandeelhouders zijn het afgelopen jaar verwaterd

Vimian Group AB (publ) Concurrenten

Xvivo Perfusion

OM:XVIVO

SEK 14.2b

Bactiguard Holding

OM:BACTI B

SEK 1.2b

OssDsign

OM:OSSD

SEK 786.2m

Elekta

OM:EKTA B

SEK 24.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Vimian Group
Historische aandelenkoersen
Huidige aandelenkoers	SEK 44.00
52 Week Hoogtepunt	SEK 47.20
52 Week Laag	SEK 23.54
Bèta	1.6
11 maand verandering	4.51%
3 maanden verandering	7.84%
1 Jaar Verandering	75.16%
33 jaar verandering	-44.30%
5 jaar verandering	n/a
Verandering sinds IPO	-45.61%

Recent nieuws en updates

Recent updates

Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Aug 31

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Aug 17

Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 18

Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Apr 09

There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

Nov 01

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price

Aug 27

When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?

Jul 19

Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?

May 19

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Apr 04

Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Jan 06

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Dec 09

Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 38% Discount?

Aug 25

We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)

Jun 18

Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 34% Discount?

May 19

Does This Valuation Of Vimian Group AB (publ) (STO:VIMIAN) Imply Investors Are Overpaying?

Feb 07

Risks Still Elevated At These Prices As Vimian Group AB (publ) (STO:VIMIAN) Shares Dive 28%

Nov 30

Rendement voor aandeelhouders

	VIMIAN	SE Medical Equipment	SE Markt
7D	4.0%	-2.6%	-0.2%
1Y	75.2%	-6.3%	11.8%

Rendement versus industrie: VIMIAN overtrof de Swedish Medical Equipment industrie, die het afgelopen jaar een rendement -6.3 % opleverde.

Rendement versus markt: VIMIAN overtrof de Swedish markt, die het afgelopen jaar een rendement opleverde van 11.8 %.

Prijsvolatiliteit

Is VIMIAN's price volatile compared to industry and market?
VIMIAN volatility
VIMIAN Average Weekly Movement	4.6%
Medical Equipment Industry Average Movement	7.4%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.3%
10% least volatile stocks in SE Market	3.3%

Stabiele aandelenkoers: VIMIAN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van VIMIAN is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2020	1,100	Patrik Eriksson	vimian.com

Vimian Group AB (publ) houdt zich wereldwijd bezig met diergezondheid. Het bedrijf is actief in de segmenten Specialty Pharma, MedTech, Diagnostics en Veterinary Services. Het bedrijf biedt eigen diagnostica, behandelingen op recept en behandelingen zonder recept voor preventieve zorg en behandeling van chronische aandoeningen voor gezelschapsdieren onder de merknaam Nextmune; en moleculaire en immunodiagnostische oplossingen die worden gebruikt door laboratoria voor veterinaire specifieke toepassingen met een focus op de markten voor vee en gezelschapsdieren onder de merknaam Indical Bioscience.

Vimian Group AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Vimian Group zich tot de beurswaarde?
VIMIAN fundamentele statistieken
Marktkapitalisatie	SEK 23.02b
Inkomsten(TTM)	SEK 2.95m
Inkomsten(TTM)	SEK 4.05b

7,816x

Koers/Winstverhouding

5.7x

P/S-verhouding

Is VIMIAN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VIMIAN resultatenrekening (TTM)
Inkomsten	€352.39m
Kosten van inkomsten	€105.67m
Brutowinst	€246.72m
Overige uitgaven	€246.46m
Inkomsten	€256.00k

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 13, 2025

Winst per aandeel (EPS)	0.00049
Brutomarge	70.01%
Nettowinstmarge	0.073%
Schuld/Eigen Vermogen Verhouding	35.9%

Hoe presteerde VIMIAN op de lange termijn?

Bekijk historische prestaties en vergelijking

VIMIAN Overzicht aandelen

Beloningen

Risicoanalyse

Vimian Group AB (publ) Concurrenten

OM:XVIVO

SEK 14.2b

OM:BACTI B

SEK 1.2b

OM:OSSD

SEK 786.2m

OM:EKTA B

SEK 24.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Consensus EPS estimates increase by 13%

Now 20% undervalued

Third quarter 2024 earnings released: €0.004 loss per share (vs €0.016 profit in 3Q 2023)

Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025

Now 21% undervalued

Consensus EPS estimates increase by 16%

Recent updates

Consensus EPS estimates increase by 13%

Now 20% undervalued

Third quarter 2024 earnings released: €0.004 loss per share (vs €0.016 profit in 3Q 2023)

Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025

Now 21% undervalued

Consensus EPS estimates increase by 16%

Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Consensus EPS estimates fall by 17%

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Second quarter 2024 earnings: EPS misses analyst expectations

Chief Executive Officer of Nextmune recently sold kr3.6m worth of stock

Director recently bought kr10m worth of stock

Vimian Group AB (publ) Elects Magnus Welander to Board as Chairman of the Board

New minor risk - Earnings quality

Independent Director recently bought kr386k worth of stock

Consensus EPS estimates fall by 24%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Full year 2023 earnings: EPS misses analyst expectations

Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion.

Full year 2023 earnings released: EPS: €0.022 (vs €0.017 loss in FY 2022)

Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital

Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues

Vimian Group AB (publ) Announces CEO Changes

Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million.

Chairman of the board recently bought kr235m worth of stock

Vimian Group AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?

Chief Executive Officer recently bought kr605k worth of stock

Vimian Group AB (publ) Announces Fredrik Ullman Step Down as CEO

Vimian Group AB (Publ) Elects Robert Belkic as New Board Member

Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?

Full year 2022 earnings released: €0.017 loss per share (vs €0.019 profit in FY 2021)

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Chief Executive Officer recently bought kr1.1m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% undervalued after recent price drop

Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Investor sentiment deteriorated over the past week

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Third quarter 2022 earnings released

Vimian Group AB (publ) to Report Q2, 2023 Results on Aug 17, 2023

High number of new and inexperienced directors

Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Vimian Appoints Carl-Johan Ehn as General Counsel and Member of the Vimian Group Management Team

Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 38% Discount?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Vimian Group AB (publ) (OM:VIMIAN) acquired Heiland Gmbh.

Vimian Group AB (publ) Appoints Carl-Johan Zetterberg Boudrie as CFO and Member of Management Team

We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)